15th International Congress on Antiphospholipid Antibodies

抗磷脂抗体(APL)是血栓形成的主要获得性危险因素。临床 症状(血栓形成、妊娠发病率)与APL一起定义为抗磷脂综合征 (APS)。深静脉血栓形成(DVT)是最常见的静脉，卒中是最常见的动脉 血栓形成；胎儿死亡、生长受限、先兆子痫和早产构成妊娠 发病率。Livedo、心脏瓣膜疾病、血小板减少、溶血性贫血、认知功能障碍和 APL阳性患者也可发生肾病。其他健康的个人或患有其他疾病的患者 自身免疫性疾病，如狼疮，可发展为急性早幼粒细胞白血病。 关于APL的国际大会每三年举行一次；传统上，大会 是来自多个学科的科学家和临床医生讨论最近的创新和 重要的研究，以确定研究问题的优先顺序，并为未来的研究制定路线图。在每个 大会，国际执行委员会成员就地点、主席和议程提出建议并进行投票 参加下一次会议。2013年9月，在巴西里约热内卢举行的第14届大会上，多鲁克博士 纽约州纽约特殊外科医院风湿病副主治医师埃尔坎当选 将于2016年9月在土耳其伊斯坦布尔主持下一届大会。 自1984年以来，共召开了14次APL国际会议：描述了APS的临床现象； 根据抗原特性定义的分类标准和机制；描述的非标准 并探索了新的机制，如内皮激活、滋养层功能和 微生物组。该领域仍然缺乏强有力的临床试验、风险预测和精确的靶向治疗。 APS基础和临床科学的最新进展使我们能够解决这些缺陷。在 在大会期间，我们将准备讨论有关抗体来源机制的新发现。 以及APS的作用、损伤机制，制定新的APS分类标准，并讨论APS的临床试验 使用新一代口服抗凝剂和免疫抑制剂。 第15届国际APL大会将提供一项全面的计划，包括：证据- 基于国际公认的医生和科学家的最新演示；特别工作组 演示文稿；口头和海报提交的摘要演示文稿；会见专家研讨会；卫星 研讨会；和病人教育讲习班。会议形式新颖，由20个小组主持 由科学规划委员会在会前提出的初步答复一般 APL/APS问题来源于循证文献回顾和讨论。这些团队将 在每次讨论中包括来自不同学科的观点，以巩固现有知识和 引导新的研究。会议将产生一本最先进的《APS课本》。

Antiphospholipid antibodies (aPL) constitute a major acquired risk factor for thrombosis. Clinical symptoms (thrombosis, pregnancy morbidity) together with aPL define the antiphospholipid syndrome (APS). Deep vein thrombosis (DVT) is the most common venous and stroke is the most common arterial thrombosis; fetal death, growth restriction, pre-eclampsia, and prematurity constitute the pregnancy morbidity. Livedo, heart valve disease, thrombocytopenia, hemolytic anemia, cognitive dysfunction, and nephropathy can also occur in aPL-positive patients. Otherwise healthy individuals or patients with other autoimmune disorders, e.g., lupus may develop aPL. The International Congress on aPL takes place every three years; traditionally, the congress has been a venue for scientists and clinicians from multiple disciplines to discuss recent innovative and important studies to prioritize research questions, and to set a roadmap for future research. During each congress, International Executive Committee Members propose and vote on a location, chair, and agenda for the next meeting. During the 14th Congress in Rio de Janeiro, Brazil in September 2013, Dr. Doruk Erkan, Associate Attending Rheumatologist at the Hospital for Special Surgery, New York, NY was elected to chair the next congress in Istanbul, Turkey in September 2016. Since 1984, 14 International Congresses on aPL have: described the clinical phenomena of APS; defined classification criteria and mechanisms based on antigen characteristics; described non-criteria manifestations; and explored new mechanisms, e.g., endothelial activation, trophoblast function, and microbiome. The field still lacks robust clinical trials, risk prediction, and precisely targeted therapies. Recent advances in both the basic and clinical sciences of APS permit us to address these deficits. At the time of the Congress, we will be poised to address new findings regarding mechanisms of antibody origin and effect, mechanisms of injury, develop new classification criteria for APS, and discuss APS clinical trials with new generation oral anticoagulants and immunosuppressive agents. The 15th International Congress on aPL will offer a comprehensive program including: evidence- based state-of-the art presentations from internationally recognized physicians and scientists; Task Force presentations; oral and poster submitted abstract presentations; meet the expert workshops; satellite symposiums; and patient education workshops. The format of the meeting is novel in that 20 teams chaired by the Scientific Planning Committee, prior to the meeting, will present tentative answers to general aPL/APS questions derived from evidence-based literature review and discussions. These teams will include points of view from different disciplines in each discussion to consolidate existing knowledge and guide new research. The meeting will produce a “State-of-the-art” APS Text Book”.